eprintid: 10196073 rev_number: 10 eprint_status: archive userid: 699 dir: disk0/10/19/60/73 datestamp: 2024-08-22 09:22:53 lastmod: 2025-01-20 14:52:08 status_changed: 2024-08-22 09:22:53 type: article metadata_visibility: show sword_depositor: 699 creators_name: Sim, Sing Yue creators_name: Chalkiadaki, Evangelia creators_name: Koutsocheras, Georgios creators_name: Nicholson, Luke creators_name: Sivaprasad, Sobha creators_name: Patel, Praveen J creators_name: Selvam, Senthil creators_name: Pal, Bishwanath creators_name: Keane, Pearse A creators_name: Bhatia, Bhairavi creators_name: Hamilton, Robin creators_name: Logeswaran, Abison creators_name: Tufail, Adnan creators_name: Gurbaxani, Avinash creators_name: pal, Bishwanath creators_name: Egan, Catherine creators_name: Bessant, David creators_name: Thomas, Dhanes creators_name: Ling, Heng creators_name: Huemer, Josef creators_name: Basheer, Khadijah creators_name: Balaskas, Konstantinos creators_name: Bouras, Konstantinos creators_name: Da Cruz, Lyndon creators_name: Natkunarajah, Mythili creators_name: Okhravi, Narciss creators_name: Islam, Niaz creators_name: Desai, Parul creators_name: Addison, Peter creators_name: Rajendram, Ranjan creators_name: Esposti, Simona creators_name: Heeren, Tjebo creators_name: Rahman, Waheeda creators_name: Khan, Yasir creators_name: Ockrim, Zoe creators_name: Saihan, Zubin title: Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D08 note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. abstract: Purpose: To report 1-year anatomic and functional real-world outcomes of patients with treatment-intensive neovascular age-related macular degeneration (nAMD) switched to faricimab. Design: Retrospective multicenter cohort study. Subjects: Consecutive nAMD patients on 4-weekly treatment interval with either ranibizumab or aflibercept 2 mg in the last 3 visits within a treat-and-extend protocol (high treatment burden) before switch to faricimab at Moorfields Eye Hospital between September 5, 2022 and December 5, 2022. Methods: Patients with nAMD switched to faricimab were identified from electronic medical records and those who met criteria of high treatment burden were included. Data collected included preswitch and postswitch visual acuity (VA), treatment intervals, baseline macular morphology, central subfield thickness (CST), macular fluid status, and adverse events. Main Outcome Measures: Visual acuity, CST, presence of intraretinal fluid, subretinal fluid, and injection intervals over 1 year after switch to faricimab. Results: A total of 130 of 286 (45.5%) eyes met inclusion criteria of being switched due to high treatment burden and 117 were included in analysis. Before switch, these eyes received mean total number of injections of 33.4 ± 19.6 over a mean of 51.3 ± 34.9 months. Mean number of injections in 12 months preceding switch was 10.1 ± 1.6 and mean interval of the preceding 3 injections was 4.2 ± 0.3 weeks. Mean VA, CST, and percentage of patients with dry macula before switch were 66.0 ± 11.9 ETDRS letters, 259.6 ± 76.0 μm and 18.3% respectively. After switch, there was no statistical difference in mean VA throughout follow-up period. Mean CST statistically significantly reduced after the third faricimab injection and at 12 months by 20.0 μm (P = 0.035) and 22.1 μm (P = 0.041) respectively. Mean treatment intervals increased to 6.9 ± 2.3 weeks (P < 0.005) at 12 months with 42.9% and 11.4% of patients being on ≥8-weekly and ≥12-weekly treatment intervals, respectively. Conclusions: At 12 months, nAMD patients with previous record of high treatment burden when switched to faricimab maintained VAs and improved anatomic outcomes on extended treatment intervals. Physician bias is inherent in these types of observational studies so a prospective, randomized, controlled trial is recommended to validate these findings. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. date: 2025-01-02 date_type: published publisher: Elsevier BV official_url: http://dx.doi.org/10.1016/j.oret.2024.07.020 full_text_type: other language: eng verified: verified_manual elements_id: 2302437 doi: 10.1016/j.oret.2024.07.020 medium: Print-Electronic pii: S2468-6530(24)00355-5 lyricists_name: Keane, Pearse lyricists_name: Patel, Praveen lyricists_name: Sivaprasad, Sobha lyricists_name: Okhravi, Narciss lyricists_name: Rajendram, Ranjan lyricists_name: Tufail, Adnan lyricists_id: KPEAR28 lyricists_id: PJPAT43 lyricists_id: SSIVA97 lyricists_id: NOKHR99 lyricists_id: RRAJE35 lyricists_id: ATUFA08 actors_name: Keane, Pearse actors_id: KPEAR28 actors_role: owner full_text_status: restricted publication: Ophthalmology Retina volume: 9 number: 1 pagerange: 22-30 event_location: United States citation: Sim, Sing Yue; Chalkiadaki, Evangelia; Koutsocheras, Georgios; Nicholson, Luke; Sivaprasad, Sobha; Patel, Praveen J; Selvam, Senthil; ... Saihan, Zubin; + view all <#> Sim, Sing Yue; Chalkiadaki, Evangelia; Koutsocheras, Georgios; Nicholson, Luke; Sivaprasad, Sobha; Patel, Praveen J; Selvam, Senthil; Pal, Bishwanath; Keane, Pearse A; Bhatia, Bhairavi; Hamilton, Robin; Logeswaran, Abison; Tufail, Adnan; Gurbaxani, Avinash; pal, Bishwanath; Egan, Catherine; Bessant, David; Thomas, Dhanes; Ling, Heng; Huemer, Josef; Basheer, Khadijah; Balaskas, Konstantinos; Bouras, Konstantinos; Da Cruz, Lyndon; Natkunarajah, Mythili; Okhravi, Narciss; Islam, Niaz; Desai, Parul; Addison, Peter; Rajendram, Ranjan; Esposti, Simona; Heeren, Tjebo; Rahman, Waheeda; Khan, Yasir; Ockrim, Zoe; Saihan, Zubin; - view fewer <#> (2025) Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab. Ophthalmology Retina , 9 (1) pp. 22-30. 10.1016/j.oret.2024.07.020 <https://doi.org/10.1016/j.oret.2024.07.020>. document_url: https://discovery.ucl.ac.uk/id/eprint/10196073/1/ORET-D-24-00242.pdf